How dopamine was recognised as a neurotransmitter: A personal view

Parkinsonism and Related Disorders

Volumn 6, Issue 2, 2000, Pages 63-67

  Sourkes, T L ^a  

^a Pharmacology and Therapeutics   (Canada)

Author keywords

Aldomet; Decarboxylase; Dopamine; Homovanillic acid; L DOPA; Methyldopa; Nigrostriatal tract; Noradrenaline; Striatum; Substantia nigra

Indexed keywords

DOPAMINE; NEUROTRANSMITTER;

ANIMAL EXPERIMENT; ANIMAL MODEL; CORPUS STRIATUM; HUMAN; MEDICAL RESEARCH; MONKEY; NEUROTRANSMISSION; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; SUBSTANTIA NIGRA;

EID: 0033997776     PISSN: 13538020     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1353-8020(99)00053-X     Document Type: Short Survey

References (70)

1. Barger G., Ewins A.J. Some phenolic derivatives of β-phenylethylamine. J Chem Soc. 97:1910;2253.
2. Mannich C., Jacobsohn W. Über Oxyphenylalkylamine und Dioxyphenylalkylamine. Ber dtsch Chem Ges. 43:1910;187-197.
3. Barger G., Dale H.H. Chemical structure and sympathomimetic action of amines. J Physiol. 41:1910;19-59.
4. Sourkes T.L., Gauthier S. Levodopa and dopamine agonists in the treatment of Parkinson's disease. Parnham M.J., Bruinvels J. Discoveries in pharmacology, psycho- and neuro-pharmacology. 1:1983;249-267 Elsevier, Amsterdam.
5. Holtz P., Credner K., Koepp W. Die enzymatische Entstehung von Oxytyramin im Organismus und die physiologische Bedeutung der Dopadecarboxylase. Arch Exp Path Pharmakol. 200:1942;356-388.
6. Holtz P., Credner K., Kroneberg G. Über das sympathicomimetische pressorische Prinzip des Harns (Urosympathin). Arch Exp Path Pharmakol. 204:1947;228-243.
7. von Euler U.S., Hamberg U., Hellner S. β-(3,4-Dihydroxyphenyl)ethylamine (hydroxytyramine) in normal human urine. Acta Physiol Scand. 49:1951;655-658.
8. Goodall M. Studies of adrenaline and noradrenaline in mammalian hearts and suprarenals. Acta Physiol Scand. 24:(Suppl. 85):1951;7-51.
9. Shepherd D.M., West G.B. Hydroxytyramine and the adrenal medulla. J Physiol. 120:1953;15-19.
10. Dengler H. Über das Vorkommen von Oxytyramin in der Nebenniere. Ch Exp Path Pharmakol. 231:1957;373-377.
11. Schümann H.J. Nachweis von Oxytyramin (Dopamin) in sympathischen Nerven und Ganglien. Arch Exp Path Pharmakol. 277:1956;566-573.
12. Carlsson A., Lindqvist M., Magnusson T., Waldeck B. On the presence of 3-hydroxytyramine in brain. Science. 127:1958;471.
13. Montagu K.A. Catechol compounds in rat tissues and in brains of different animals. Nature. 180:1957;244-245.
14. Sano I., Gamo T., Kakimoto Y., Taniguchi K., Takesada M., Nishinuma K. Distribution of catechol compounds in human brain. Biochem Biophys Acta. 32:1959;586-587.
15. Sano I., Taniguchi K., Gamo T., Takesada M., Kakimoto Y. Die Katecholamine im Zentralnervensystem. Klin Wochschr. 38:1960;57-62.
16. Bertler A., Rosengren E. Occurrence and distribution of dopamine in brain and other tissues. Experientia. 15:1964;10-11.
17. Sourkes T.L. Actions of dopa and dopamine in relation to function of the central nervous system. Biochemical and neurophysiological correlation of centrally acting drugs. Proceedings of the Second International Pharmacological Meeting, Prague, August 1963. 1964;35-50 Pergamon and Czechoslovak Medical Press, Prague.
18. Sourkes T.L. Central actions of dopa and dopamine. Rev Canad de Biol. 31:(Suppl):1972;153-168.
19. Sourkes T.L. Actions of levodopa and dopamine in the central nervous system. J Am Med Assoc. 218:1971;1909-1911.
20. Carlsson A., Lindqvist M., Magnusson T. 3,4-Dihydroxyphenylalanine and 5-hydroxytryptophan as reserpine antagonists. Nature. 180:1957;1200-1201.
21. Degkwitz R., Frowein R., Kulenkampff C., Mohs U. Über die Wirkungen des L-DOPA beim Menschen und deren Beeinflussung durch Reserpin, Chlorpromazin, Iproniazid und Vitamin B6. Klin Wochschr. 38:1960;120-123.
22. Carlsson A. Autobiography Squire L.R. The history of neuroscience in autobiography. 2:1998;28-66 Academic Press, San Diego, CA.
23. Hornykiewicz O. From dopamine to Parkinson's disease: a personal research record. Samson F., Adelman G. The neurosciences: paths of discovery. II:1992;125-146 Birkhäuser, Boston.
24. Sourkes T.L. Cerebral and other diseases with disturbances of amine metabolism. Progr Br Res. 8:1964;186-200.
25. Sourkes T.L. Metabolism of monoamines in extrapyramidal disorders. de Ajuriaguerra J., Gauthier G. Monoamines, noyaux gris centraux et syndrome de Parkinson. 1971;129-141 Masson, Geneva.
26. Sourkes T.L., Poirier L.J. Amines of the striatum: relation to experimental tremor in the monkey. Costa E., Côté L.J., Yahr M.D. Biochemistry and pharmacology of the basal ganglia. 1966;187-194 Raven Press, Hewlett, NY.
27. Poirier L.J., Sourkes T.L. Experimentally induced parkinsonism. Neurotransmitters Assoc Res Nervous Mental Disorders. 50:1972;416-432.
28. Sourkes T.L., Poirier L.J., Lal S. Diseases of the basal ganglia. Good R.A., Day S.B., Yunis J.J. Molecular pathology. 1975;689-743 Thomas, Springfield, IL.
29. Sourkes T.L. Reflections at seventy. J Neural Transm. 29:(Suppl):1990;5-12.
30. Sourkes T.L. Inhibition of dihydroxyphenylalanine decarboxylase by derivatives of phenylalanine. Arch Biochem Biophys. 51:1954;444-456.
31. Barbeau A., Murphy G.F., Sourkes T.L. Excretion of dopamine in diseases of the basal ganglia. Science. 133:1961;1706-1707.
32. Barbeau A., Sourkes T.L., Murphy G.F. Les catécholamines dans la maladie de Parkinson. de Ajuriaguerra. Monoamines et système nerveux central. 1962;247-262 Geoug and Paris: Masson, Geneva.
33. Ehringer H., Hornykiewicz O. Verteilung von Noradrenalin und Dopamin (3-Hydroxytyramin) im Gehirn des Menschen und ihr Verhalten bei Erkrankungen des extrapyramidalen Systems. Klin Wochschr. 38:1960;1236-1239.
34. Sourkes T.L. Catecholamine metabolism and some functions of the nervous system. Am J Clin Nutr. 12:1963;321-329.
35. Papeschi R., Molina-Negro P., Sourkes T.L., Hardy J., Bertrand C. Concentration of homovanillic acid in the ventricular fluid of patients with Parkinson's disease and other dyskinesias. Neurology. 20:1970;991-995.
36. Papeschi R., Molina-Negro P., Sourkes T.L., Erba G. The concentration of homovanillic and 5-hydroxyindoleacetic acids in ventricular and lumbar CSF. Neurology. 22:1972;1152-1159.
37. Murphy G.F., Sourkes T.L. Effect of catecholamino acids on the catecholamine content of rat organs. Rev Canad de Biol. 18:1959;379-388.
38. Sourkes T.L. Formation of dopamine in vivo: relation to the function of the basal ganglia. Rev Canad de Biol. 20:1961;187-196.
39. Sourkes T.L. "Rational hope" in the early treatment of Parkinson's disease. Can J Physiol Pharmacol. 77:1999;375-382.
40. Birkmayer W., Hornykiewicz O. Der L-Dioxyphenylalanin (=L-DOPA)-Effekt beim Parkinson-Syndrom des Menschen: zur Pathogenese und Behandlung der Parkinson-Akinese. Arch Psychiat Nervenkr. 203:1962;560-574.
41. Cotzias G., Van Woert M., Schiffer L. Aromatic amino acids and modification of parkinsonism. N Eng J Med. 276:1967;374-379.
42. Roe D.L. From DOPA to Parkinson's disease: the early history of dopamine research. J Hist Neurosci. 6:1997;291-301.
43. Foix C., Nicolesco J. Anatomie cérébrale; les noyaux gris centraux et la région mésencéphalo-sous-optique. 1925;Masson, Paris.
44. Hassler R. Zur Pathologie der Paralysis agitans und des Post-Encephalitischen Parkinsonismus. J Psychol Neurol (Leipzig). 48:1938;367-388.
45. Adams R., Van Bogaert L., Van der Eecken H. Dégénérescences nigrostriées et cérébello-nigro-striées. Psychiat et Neurol. 142:1961;219-259.
46. Poirier L.J. Experimental and histological study of midbrain dyskinesias. J Neurophysiol. 23:1960;534-551.
47. Ferraro A. The connections of the pars suboculomotoria of the substantia nigra. Arch Neurol Psychiat. 19:1928;177-179.
48. Poirier L.J., Sourkes T.L. Influence of the substantia nigra on the catecholamine content of the striatum. Brain. 88:1965;181-192.
49. Poirier L.J., Sourkes T.L. Contribution neuro-anatomique et neurochimique à l'étude du tremblement de type parkinsonnien. Actualités Neurophysiol. 6:1965;167-181.
50. Poirier L.J., Sourkes T.L., Bouvier G., Boucher R., Carabin S. Striatal amines, experimental tremor and the effect of harmaline in the monkey. Brain. 89:1966;37-52.
51. Sourkes T.L., Poirier L.J. Influence of the substantia nigra on the concentration of 5-hydroxytryptamine and dopamine of the striatum. Nature. 207:1965;202-203.
52. Sourkes T.L., Poirier L.J. Effect of brain stem lesions on the concentration of catecholamines in basal ganglia of the monkey. J Neurosurg. 24:(Suppl):1966;194-195.
53. Poirier L.J., Sourkes T.L. Influence du locus niger sur la concentration des catécholamines du striatum. J Physiologie. 56:1964;426-427.
54. Sourkes T.L. Amines of the basal ganglia: biochemical, pharmacological and neurological studies. Walaas. The molecular basis of some aspects of mental activity. 1967;443-448 Academic Press, New York.
55. Sourkes T.L., Poirier L.J., Singh P. Biochemical-histological-neurological models of Parkinson's disease. Gillingham F.J., Donaldson I.M.L. Third Symposium on Parkinson's Disease. 1969;54-60 Livingstone, Edinburgh.
56. Sourkes T.L., Pivnicki D., Brown W.T., Wiseman-Distler M.H., Murphy G.F., Sankoff I., Saint Cyr S. A clinical and metabolic study of dopa (3,4-dihydroxyphenylalanine) and methyldopa in Huntington's chorea. Psychiatria et Neurologia (Basel). 149:1965;7-27.
57. Bédard P., Larochelle L., Poirier L.J., Sourkes T.L. Reversible effect of L-DOPA on tremor and catatonia induced by α-methyl-p-tyrosine. Can J Physiol Pharmacol. 48:1970;82-84.
58. Larochelle L., Bédard P., Poirier L.J., Sourkes T.L. Correlative neuroanatomical and neuropharmacological study of tremor and catatonia in the monkey. Neuropharmacology. 10:1971;273-288.
59. Sharman D.F., Poirier L.J., Murphy G.F., Sourkes T.L. Homovanillic acid and dihydroxyphenylacetic acid in the striatum of monkeys with brain lesions. Can J Physiol Pharmacol. 45:1967;57-62.
60. Bernheimer H., Hornykiewicz O. Herabgesetzte Konzentration der Homovanillinsäure im Gehirn von parkinsonkranken Menschen als Ausdruck der Störung des zentralen Dopaminwechsels. Klin Wochschr. 43:1965;711-715.
61. Poirier L.J., Singh P., Sourkes T.L., Boucher R. Effect of amine precursors on the concentration of striatal dopamine and serotonin in cats with and without unilateral brain lesions. Brain Res. 6:1967;654-666.
62. Lancaster G., Larochelle L., Bédard P., Missala K., Sourkes T.L., Poirier L.J. Effect of brain lesions and of harmaline on the DOPA decarboxylase activity ion the striatum of the cat. J Neurol Sci. 11:1970;265-274.
63. Duncan R.J.S., Sourkes T.L., Boucher R., Poirier L.J., Roberge A. Aldehyde dehydrogenase and monoamine oxidase in the striatum of cats with nigrostriatal lesions. J Neurochem. 19:1972;2007-2010.
64. Andén N.E., Carlsson A., Dahlström, Fuxe K., Hillarp N.Å., Larsson K. Demonstration and mapping out of nigro-neostriatal dopamine neurons. Life Sci. 3:1964;535-540.
65. Andén N.E., Dahlström A., Fuxe K., Larsson K. Further evidence for the presence of nigro-neostriatal dopamine neurons in the rat. Am J Anat. 116:1965;329-333.
66. Goldstein M., Battista A.F., Anagnoste B., Nakatani S. Tremor production and striatal amines in monkeys. Gillingham F.J., Donaldson I.M.L. Third Symposium on Parkinson's Disease. 1969;37-40 Livingstone, Edinburgh.
67. Battista A.F., Goldstein M., Nakatani S., Anagnoste B. The effects of ventrolateral thalamic lesions on tremor and the biosynthesis of dopamine in monkeys with lesions in the ventromedial tegmentum. J Neurosurg. 31:1969;164-171.
68. Goldstein M., Anagnoste B., Owen W.S., Battista A.F. The effects of ventromedial tegmental lesions on the biosynthesis of catecholamines in the striatum. Life Sci. 5:1966;2171-2176.
69. Sourkes T.L. Significance of dopamine for the brain sciences. de la Fuente R., Weisman M.N. Proceedings of the Vth World Congress of Psychiatry, Mexico, Amsterdam: Excerpta Med. 274:1974;56-62.
70. Sourkes T.L. Neural and neuroendocrine functions of dopamine. Psychoneuroendocrinology. 1:1975;69-78.